Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 19/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28952435 | 0.85 | NR1H2 (0.33) | GLP1RTHRB | |
| SCHEMBL20014821 | 0.85 | NR1H2 (0.33) | GLP1RTHRB | |
| SCHEMBL31638138 | 0.84 | USP30 (0.34) | GLP1RTHRB | |
| SCHEMBL26122776 | 0.83 | GLP1R (0.36) | GLP1R | |
| SCHEMBL31011024 | 0.83 | GLP1R (0.37) | GLP1R | |
| SCHEMBL20014787 | 0.83 | GLP1R (0.36) | GLP1R | |
| SCHEMBL31472076 | 0.83 | GLP1R (0.36) | GLP1R | |
| SCHEMBL31424405 | 0.83 | THRB (0.33) | GLP1RTHRB | |
| SCHEMBL31692337 | 0.83 | THRB (0.33) | GLP1RTHRB | |
| SCHEMBL25025228 | 0.82 | GLP1R (0.40) | GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665730-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12291529-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20240376105-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240327404-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-10-03 | — | — | US | disclosed |
| WO-2024169952-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376105-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, IAPP | GLP1R 1/4885THRB 159/4885 |
| US-12291529-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, IAPP | GLP1R 1/4885THRB 159/4885 |
| US-20240327404-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, IAPP | GLP1R 1/4885THRB 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.